Transthyretin (TTR) Y78F Variant Filaments
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: Yes


Transthyretin (TTR) Y78F Variant Filaments
Background:
Transthyretin is a transport protein in the serum and cerebospinal fluid that carried the thyroid hormone Thyroxine and retinol-binding protein bound to retinol. TTR misfolding and aggregation is known to be associated with the amyloiddiseases SSA, FAP and FAC (1-5) . TTR is also thought to have beneficial side effects, such as binding to beta-amyloid protein, preventing beta-amyloid from accumulating into the plaques associated with Alzheimer's Disease (6) . The mutant variant Y78F indicates a destabilization of the contacts between the alpha-helix and AB loop and the body of the molecule, potentially leading to applications in immne therapy for FAP (7) .Description:
Human Recombinant Transthyretin (TTR) Y78F Variant FilamentsProduct Name Alternative:
Amyloid polyneuropathy Protein, Amyloidosis I Protein, ATTR Protein, Carpal tunnel syndrome 1 Protein, CTS Protein, CTS1 Protein, HEL111 Protein, HsT2651 Protein, PALB Protein, Prealbumin Protein, Prealbumin amyloidosis type I Protein, Prealbumin Thyroxine-binding Protein, TBPA Protein, Thyroxine binding prealbumin Protein, Transthyretin Protein, TTHY_HUMAN Protein, TTR ProteinUNSPSC:
12352202UN Code:
Non-hazardousHazard Statement:
Non-hazardousGene ID:
7276Swiss Prot:
P02766Accession Number:
NP_000362.1Cellular Locus:
Cytoplasm | Extracellular exosome | Extracellular Region | LysosomeExpression System:
E. coliHost:
E. coliOrigin Species:
HumanTarget:
Transthyretin (TTR)Conjugation:
No TagNature:
RecombinantApplications:
WB | SDS-PAGE | In vivo assay | In vitro assayField of Research:
Neuroscience | Neurodegeneration | Alzheimer's Disease | ALS Disease | Tangles & Tau | Parkinson's Disease | Cardiovascular System | Blood | Cell Signaling | Metabolism | Lipid and lipoprotein MetabolismPurification Method:
Ion-exchange PurifiedPurification:
Ion-exchange PurifiedLimit Of Detection:
Certified >95% pure using SDS-PAGE analysis. Low endotoxin <5 EU/mL @ 2mg/mL.Concentration:
Lot/batch specific. See included datasheet.Purity:
>95%Weight:
0.2Length:
Full lengthBuffer:
PBS pH 7.4Molecular Weight:
13.876 kDaPrecautions:
Not for use in humans. Not for use in diagnostics or therapeutics. For research use only.Additionnal Information:
For best results, sonicate immediately prior to use. Refer to the Neurodegenerative Protein Handling Instructions on our website, or the product datasheet for further information. Monomer source is catalog# SPR-452.References & Citations:
1. Zeldenrust S.R., Benson M.D. (2010). Wiley. pp. 795–815. 2. Westermark P., Sletten K., Johansson B., Cornwell G.G. (1990). Proc. Natl. Acad. Sci. U.S.A. 87(7): 2843–5. 3. Andrade C. (1952). Brain. 75(3): 408–27. 4. Coelho T. (1996). Curr. Opin. Neurol. 9(5): 355–9. 5. Jacobson D.R, et. al. (1997). N. Engl. J. Med. 336(7): 466–73. 6. Li X. (2011). Mol Neurodegener. 6(1):79. 7. Terazaki H.,m et al. (2006) Lab Invest. 86(1): 23-31.Shipping Conditions:
Dry Ice. Shipping note: Product will be shipped separately from other products purchased in the same order.Storage Conditions:
-80ºCNotes:
For best results, sonicate immediately prior to use. Refer to the Neurodegenerative Protein Handling Instructions on our website, or the product datasheet for further information. Monomer source is catalog# SPR-452.Protein Length:
Full lengthBackground Reference 01:
1. Zeldenrust S.R., Benson M.D. (2010) . Wiley. pp. 795–815. 2. Westermark P., Sletten K., Johansson B., Cornwell G.G. (1990) . Proc. Natl. Acad. Sci. U.S.A. 87 (7) : 2843–5. 3. Andrade C. (1952) . Brain. 75 (3) : 408–27. 4. Coelho T. (1996) . Curr. Opin. Neurol. 9 (5) : 355–9. 5. Jacobson D.R, et. al. (1997) . N. Engl. J. Med. 336 (7) : 466–73. 6. Li X. (2011) . Mol Neurodegener. 6 (1) :79. 7. Terazaki H., m et al. (2006) Lab Invest. 86 (1) : 23-31.Location:
Cytoplasm | Extracellular exosome | Extracellular Region | LysosomeImmunogen Species:
Human
MSDS Document
View Document